Business Description
Finch Therapeutics Group Inc
NAICS : 325412
SIC : 2834
Description
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.94 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 1.19 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -13.31 | |||||
| Beneish M-Score | -7.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -60.5 | |||||
| 3-Year EBITDA Growth Rate | -46.6 | |||||
| 3-Year EPS without NRI Growth Rate | -49.1 | |||||
| 3-Year FCF Growth Rate | -45.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.34 | |||||
| 9-Day RSI | 65.16 | |||||
| 14-Day RSI | 55.82 | |||||
| 6-1 Month Momentum % | -53.81 | |||||
| 12-1 Month Momentum % | -86.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.13 | |||||
| Quick Ratio | 6.13 | |||||
| Cash Ratio | 5.9 | |||||
| Days Sales Outstanding | 449.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.5 | |||||
| Shareholder Yield % | -93.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -50801.74 | |||||
| Net Margin % | -87228.7 | |||||
| FCF Margin % | -36640 | |||||
| ROE % | -165.4 | |||||
| ROA % | -90.16 | |||||
| ROIC % | -93.78 | |||||
| ROC (Joel Greenblatt) % | -150.06 | |||||
| ROCE % | -58.41 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 53.33 | |||||
| PB Ratio | 0.24 | |||||
| Price-to-Tangible-Book | 0.26 | |||||
| EV-to-EBIT | -0.14 | |||||
| EV-to-Forward-EBIT | -0.13 | |||||
| EV-to-EBITDA | -0.15 | |||||
| EV-to-Forward-EBITDA | -0.16 | |||||
| EV-to-Revenue | 70.95 | |||||
| EV-to-Forward-Revenue | 73.6 | |||||
| EV-to-FCF | -0.19 | |||||
| Earnings Yield (Greenblatt) % | -714.29 | |||||
| FCF Yield % | -683.36 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FNCH
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Finch Therapeutics Group Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.115 | ||
| EPS (TTM) ($) | -62.54 | ||
| Beta | 0 | ||
| Volatility % | 59.38 | ||
| 14-Day RSI | 55.82 | ||
| 14-Day ATR ($) | 0.380959 | ||
| 20-Day SMA ($) | 3.83241 | ||
| 12-1 Month Momentum % | -86.8 | ||
| 52-Week Range ($) | 3.35 - 30.6 | ||
| Shares Outstanding (Mil) | 1.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Finch Therapeutics Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Finch Therapeutics Group Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Finch Therapeutics Group Inc Frequently Asked Questions
What is Finch Therapeutics Group Inc(FNCH)'s stock price today?
The current price of FNCH is $4.19. The 52 week high of FNCH is $30.60 and 52 week low is $3.35.
When is next earnings date of Finch Therapeutics Group Inc(FNCH)?
The next earnings date of Finch Therapeutics Group Inc(FNCH) is 2024-03-22 Est..
Does Finch Therapeutics Group Inc(FNCH) pay dividends? If so, how much?
Finch Therapeutics Group Inc(FNCH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers